One also has to give credit for the company's expense control. In this climate where a few growth stocks are already under balance sheet stress due to out-of-control expenses, this company has not extravagantly dealt with their precious cash, and is able to fund product development without going cap-in-hand to the shareholders. Not sure whether delays with FDA are connected with their frugality.
Add to My Watchlist
What is My Watchlist?
